These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 19965949)

  • 1. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device.
    Siderov J; Kirsa S; McLauchlan R
    J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment.
    Yoshida J; Tei G; Mochizuki C; Masu Y; Koda S; Kumagai S
    Ann Occup Hyg; 2009 Mar; 53(2):153-60. PubMed ID: 19261696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents.
    Clark BA; Sessink PJ
    J Oncol Pharm Pract; 2013 Jun; 19(2):99-104. PubMed ID: 23292973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of surface contamination in a hospital hematology--oncology pharmacy.
    Touzin K; Bussières JF; Langlois E; Lefebvre M
    J Oncol Pharm Pract; 2009 Mar; 15(1):53-61. PubMed ID: 18772214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device.
    Guillemette A; Langlois H; Voisine M; Merger D; Therrien R; Mercier G; Lebel D; Bussières JF
    J Oncol Pharm Pract; 2014 Dec; 20(6):426-32. PubMed ID: 24395542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy perspective.
    Schulz H; Bigelow S; Dobish R; Chambers CR
    J Oncol Pharm Pract; 2005 Sep; 11(3):101-9. PubMed ID: 16390598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals.
    Acampora A; Castiglia L; Miraglia N; Pieri M; Soave C; Liotti F; Sannolo N
    Ann Occup Hyg; 2005 Oct; 49(7):611-8. PubMed ID: 15964876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden.
    Hedmer M; Georgiadi A; Bremberg ER; Jönsson BA; Eksborg S
    Ann Occup Hyg; 2005 Oct; 49(7):629-37. PubMed ID: 16126760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators.
    Crauste-Manciet S; Sessink PJ; Ferrari S; Jomier JY; Brossard D
    Ann Occup Hyg; 2005 Oct; 49(7):619-28. PubMed ID: 16126757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study comparing the efficacy of two cleaning techniques in reducing environmental contamination with cyclophosphamide.
    Touzin K; Bussières JF; Langlois E; Lefebvre M; Métra A
    Ann Occup Hyg; 2010 Apr; 54(3):351-9. PubMed ID: 20118195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning.
    Chu WC; Hon CY; Danyluk Q; Chua PP; Astrakianakis G
    J Oncol Pharm Pract; 2012 Mar; 18(1):46-51. PubMed ID: 21737485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.
    Gurusamy KS; Best LM; Tanguay C; Lennan E; Korva M; Bussières JF
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012860. PubMed ID: 29582940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of workplace contamination with platinum-containing cytostatic drugs in a veterinary hospital by introduction of a closed system.
    Kandel-Tschiederer B; Kessler M; Schwietzer A; Michel A
    Vet Rec; 2010 Jun; 166(26):822-5. PubMed ID: 20581360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PhaSeal® system: impact of its use on workplace contamination and duration of chemotherapy preparation.
    Favier B; Labrosse H; Gilles-Afchain L; Cropet C; Perol D; Chaumard N; Latour JF; Hild P
    J Oncol Pharm Pract; 2012 Mar; 18(1):37-45. PubMed ID: 21422148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs.
    Bartel SB; Tyler TG; Power LA
    Am J Health Syst Pharm; 2018 Feb; 75(4):199-211. PubMed ID: 29339374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syringe plunger contamination by hazardous drugs: a comparative study.
    Smith ST; Szlaczky MC
    J Oncol Pharm Pract; 2014 Oct; 20(5):381-5. PubMed ID: 24598373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator.
    Vyas N; Turner A; Clark JM; Sewell GJ
    J Oncol Pharm Pract; 2016 Feb; 22(1):10-9. PubMed ID: 25073678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process.
    Valero S; López-Briz E; Vila N; Solana A; Melero M; Poveda JL
    Regul Toxicol Pharmacol; 2018 Jun; 95():1-7. PubMed ID: 29510165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the decontamination of surfaces exposed to cytotoxic drugs in chemotherapy workstations.
    Roberts S; Khammo N; McDonnell G; Sewell GJ
    J Oncol Pharm Pract; 2006 Jun; 12(2):95-104. PubMed ID: 16984748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device.
    Sessink PJ; Connor TH; Jorgenson JA; Tyler TG
    J Oncol Pharm Pract; 2011 Mar; 17(1):39-48. PubMed ID: 20156932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.